The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 2

Sensitivity analyses based on various exclusion criteria for ORR.

Excluded trial	No. of trials	No. of patients	Experimental group	Control group	RR (95% CI)	value for RR	(%)	value for heterogeneity
Cortot (2020)	8	2698	1374	1324	1.56 [1.19, 2.04]	<0.01	82	<0.01
Fukuda (2019)	8	2824	1465	1359	1.56 [1.19, 2.06]	<0.01	83	<0.01
Kitagawa (2019)	8	2849	1479	1370	1.66 [1.25, 2.20]	<0.01	84	<0.01
Niho (2012)	8	2689	1368	1321	1.59 [1.18, 2.14]	<0.01	83	<0.01
Reck (2009)	8	2208	1156	1052	1.67 [1.21, 2.31]	<0.01	84	<0.01
Reck (2010)	8	2207	1155	1052	1.63 [1.19, 2.24]	<0.01	83	<0.01
Saito (2019)	8	2636	1371	1265	1.74 [1.31, 2.31]	<0.01	75	<0.01
Sandler (2006)	8	2091	1104	987	1.50 [1.16, 1.93]	<0.01	74	<0.01
Seto (2014)	8	2710	1408	1302	1.75 [1.31, 2.36]	<0.01	79	<0.01